Neue zoophage Gallmücken-Gattungen (Diptera: Itonididae).

Nomenklatorische Handlungenvasta Möhn, 1955 (Chiliodiplosis), spec. n.Chiliodiplosis Möhn, 1955 (Itonididae), gen. n.Phonodiplosis Möhn, 1955 (Itonididae), gen. n.casta Möhn, 1955 (Phonodiplosis), spec. n.Nomenclatural Actsvasta Möhn, 1955 (Chiliodiplosis), spec. n.Chiliodiplosis Möhn, 1955 (Itonididae), gen. n.Phonodiplosis Möhn, 1955 (Itonididae), gen. n.casta Möhn, 1955 (Phonodiplosis), spec. n

Cell membrane softening in human breast and cervical cancer cells

Biomechanical properties are key to many cellular functions such as cell division and cell motility and thus are crucial in the development and understanding of several diseases, for instance cancer. The mechanics of the cellular cytoskeleton have been extensively characterized in cells and artificial systems. The rigidity of the plasma membrane, with the exception of red blood cells, is unknown and membrane rigidity measurements only exist for vesicles composed of a few synthetic lipids. In this study, thermal fluctuations of giant plasma membrane vesicles (GPMVs) directly derived from the plasma membranes of primary breast and cervical cells, as well as breast cell lines, are analyzed. Cell blebs or GPMVs were studied via thermal membrane fluctuations and mass spectrometry. It will be shown that cancer cell membranes are significantly softer than their non-malignant counterparts. This can be attributed to a loss of fluid raft forming lipids in malignant cells. These results indicate that the reduction of membrane rigidity promotes aggressive blebbing motion in invasive cancer cells

Urokinaseâ deficient and urokinase receptorâ deficient mice have impaired neutrophil antimicrobial activation in vitro

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/141382/1/jlb0648.pd

Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time

Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19+ B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation stages and exhaustion markers of CAR T-cell subsets prior to CAR T-cell infusion and longitudinally during 6 months of follow-up. The majority of activation markers on CAR T-cells showed stable expression patterns over time and were not associated with response to therapy or toxicity. Unsupervised cluster analysis revealed an immune signature of CAR T-cell products associated with the development of immune cell-associated neurotoxicity syndrome. Warranting validation in an independent patient cohort, in-depth phenotyping of CAR T-cell products as well as longitudinal monitoring post cell transfer might become a valuable tool to increase efficacy and safety of CAR T-cell therapy